AACR 2026 at a glance
AACR 2026 in San Diego highlights emerging developments in cancer research, from precision oncology and liquid biopsy to engineered cell therapies, antibody-drug conjugates (ADCs), and treatment resistance.
Artificial intelligence and machine learning are also prominent themes, with applications spanning biomarker prediction, digital twins, immunotherapy selection, imaging-based risk assessment, and spatial oncology.
📅 Build your schedule around the sessions that matter most.
📥 Download the AACR 2026_Preview_by_LucidQuest
AACR 2026: Key Oncology Developments to Watch
Precision Oncology, Genomics, and Diagnostic Platforms
Real-world, population-aware platforms are expected to improve early detection, resistance monitoring, and therapy matching.
Liquid Biopsy and Blood-Based Detection
Serial plasma CGP may refine NSCLC resistance tracking, while rbcDNA screening showed 85% adenoma and 95% CRC sensitivity.
Biomarker Stratification and Equitable Genomics
WES-based HRD may outperform BRCA for PARPi selection, while large KMT2C and India–Germany datasets expand biomarker precision.
Engineered Cell Therapies and T-Cell Optimization
LM-103 showed 75% disease control, STK-012 reached 55% ORR, and next-generation CAR strategies continued to advance.
Microenvironment-Directed Immunotherapy
CBD-αCTLA4, IL-12 circRNA LNPs, and stromal-targeting combinations are expected to improve survival and immune activation.
ADCs and Next-Generation Targeted Platforms
T-DXd improved 5-year OS in HER2-amplified mCRC, while STRO-004 and ASP2998 highlighted platform diversification.
Mechanism-Guided Combination and Resistance Targeting
AURKA+KRAS, CBP/p300+PARP, REM-422, and IM156 highlight biomarker-guided strategies against resistant disease.
Microenvironment-Driven Resistance Biology
Stromal and immune circuits shaped response, including NeoTRIP B-cell niches, NAT10 inhibition, and CAF-driven suppression.
Population Risk Stratification and Diverse Epidemiology
Multi-ancestry GWAS identified 469 breast cancer loci, while large cohorts defined high-risk population subsets.
Artificial Intelligence and Machine Learning at AACR 2026
Multimodal Histology-to-Biomarker Modeling
CRC virtual genomics trained on 45,155 cases predicted broad mutation sets with TCGA external validation.
LLMs Entering Clinical Classification
CUPAI-2 combined three LLMs with XGBoost, achieving 76.93% Top-1 and 92.82% Top-3 accuracy.
Digital Twins for Treatment Optimization
OncoTwin models in ALK-positive NSCLC suggested improved risk stratification and potential PFS benefit.
AI Pathology for Immunotherapy Selection
NEPTUNE used 15 H&E-derived features, matching or outperforming PD-L1, bTMB, and ECOG.
Longitudinal Imaging Risk Models Maturing
Sybil-based LDCT models showed strong Year-1 discrimination, durable Year-6 accuracy, and external robustness.
Spatial and Foundation-Model Oncology Expanding
Integrated spatial AI and AF3+ESM2 highlighted growing progress in recurrence modeling and peptide–MHC II prediction.
Download LucidQuest’s AACR 2026 Preview Report
Download our AACR 2026 preview report for deeper analysis of precision oncology, emerging cancer therapies, biomarker-driven strategies, treatment resistance, and AI applications in cancer research.
📅 Build your schedule around the sessions that matter most.
📥 Download the AACR 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
